Keyword: Compass Therapeutics
Two years after its founding, Biomatics Capital Partners has raised $300 million for its second fund and signed on two new venture partners.
This year’s class of Fierce 15 landed during a banner year for venture capital investment in biotech. We asked them if they thought the trend would continue or if the bubble would burst.
Innovating in the next-generation form of antibodies to fight cancer and autoimmune diseases with a focus on speed and combination therapies.
All of our Fierce 15 winners care deeply about biomedical science and understand the unique pressure to translate every penny they've raised into something truly innovative for patients. And it seems this passion is infectious when it comes to luring investors.